Meetings

Daotian Fu, PhD

Introduction to Chinese Antibody Society and mAbTalk

Dr. Fu Daotian was previously the vice president and executive director of Livzon Pharmaceutical Group and also the general manager of Livzon MABPharm, Inc., a biologics development company. At Livzon, he led the biologics development efforts with one successful NDA submission and multiple programs in clinical development. Dr. Fu returned to China after spending 28 years working in the biopharmaceutical industry in the U.S. Between 1998 and 2012, he served as the vice president of R&D at Genzyme Corp., one of the top five global biotech companies (later acquired by Sanofi). During this period, Dr. Fu was responsible for CMC development of clinical stage programs, and was directly involved in global launching of five major biologics and clinical development of multiple R&D programs. Dr. Fu received his B.S. from Shandong University in China, and his Ph.D. from Iowa State University.

Christoph Rader, PhD

Next-Generation Antibody-Drug Conjugates

Christoph Rader studied biochemistry at the University of Bayreuth in Germany and biochemistry and molecular biology at the University of Zurich in Switzerland, where he received his PhD in 1995. Following postdoctoral training at The Scripps Research Institute (TSRI) in La Jolla, California, USA, he was appointed Assistant Professor at TSRI in 1999. In 2003, he was recruited as Senior Scientist to the National Cancer Institute, National Institutes of Health in Bethesda, Maryland, USA. He rejoined TSRI in Jupiter, Florida, USA as Associate Professor with Tenure in 2012 and was promoted to Professor in 2019. In 2018, he was appointed as Associate Dean of the Skaggs Graduate School of Chemical and Biological Studies at TSRI, a top ten PhD program in chemistry, biochemistry, and biology. The Rader laboratory pursues both antibody target and drug discovery strategies toward more specific and more potent treatment options for cancer patients. This includes target discovery efforts aimed at identifying new cancer cell surface antigens and drug discovery efforts based on antibody display, antibody engineering, and antibody conjugation methods. A particular focus in the Rader laboratory is devoted to antibody technologies at the interface of biology and chemistry, including the generation of molecularly defined antibody-drug conjugates (ADCs) and antibody-siRNA conjugates (ARCs) as well as chemically programmed T-cell engaging bispecific antibodies (T-biAbs) and chimeric antigen receptor T cells (CAR-Ts). Collectively, these efforts have unveiled several new antibody targets, created a panel of new antibody drugs, and led to a diverse assortment of innovative antibody technologies with broad utility for cancer therapy. Several of the targets, tools, and technologies discovered and developed in the Rader laboratory have been translated to preclinical and clinical investigations through numerous collaborations with industry, academia, and government.

Xinfang Li, PhD

ADC Product Quality Development and Control

Ph.D. in Molecular Biology and Biochemistry from Peking University in Beijing China

Post-Doctorate at Harvard University

Her work has directly impacted more than 20 product approvals by the FDA

Holds multiple patents and publications in Antibody Drug Conjugate preparation and purification technologies

She is an expert in viral clearance

Kyoji Tsuchikama, PhD

Novel Linker Technologies for Generating ADCs for Cancer Therapy

Dr. Tsuchikama is tenure-track Assistant Professor at The University of Texas Health Science Center at Houston (UTHealth). He earned a Ph.D. in organic chemistry from Waseda University in Japan in March 2010. Subsequently, he worked as a postdoctoral fellow in Janda Lab at The Scripps Research Institute and gained research experience at the interface of chemistry and biology. He joined UTHealth in July 2014 and has been leading a medicinal chemistry laboratory as a principal investigator. His research programs are currently supported by NIH, DoD, and CPRIT. His primary interest is in developing novel linker technologies for generating antibody-drug conjugates (ADCs), an emerging class of cancer chemotherapeutics, by taking advantage of the power of organic chemistry, medicinal chemistry, and chemical biology. His achievements include: 1) branched ADC linkers enabling installation of multiple drug molecules and 2) an enzymatically cleavable ADC linker with high circulation stability. With these novel technology platforms in hand, his lab is currently committed to producing next-generation ADCs with improved safety profiles and efficacy to combat cancer drug resistance and heterogeneity.

Yongxin Zhao, PhD

A novel ADC platform and the ADCs generated from the platform in the targeted treatment of cancer

coming soon!

Shan Jiang, PhD

Advancing ADCs for Transformative Cancer Therapies

Dr. Jiang studied Basic Medical Sciences at Beijing Medical University in Beijing, China. After graduation in 1993 she went to Purdue University for graduate studies, where she received her Ph.D. degree in Industrial & Physical Pharmacy. She has over twenty years of industry experience specialized in Pharmaceutical Development and worked for pharmaceutical and biotech companies including Bayer, Zymogenetics (later acquired by BMS), and Seagen Inc. In her current post at Seagen, she is leading the development of Formulation and Drug Product, Potency Assays, and Impurity Assays for all pipeline programs including antibodies, antibody-drug conjugates (ADCs) and small molecules.

Her publications include research papers, book chapters, presentations, and patents on formulation development for biologics, device evaluations, and manufacturing control strategies. She is an active member in several science and technology associations and has been invited to speak at industry conferences in US, Europe, and Asia.

Jacqueline Ming Liu, MD

Challenges in the Clinical Development of Antibody Drug Conjugates

- Chief Medical Officer, TOT BIOPHARM, 2017/9 to the present
Responsible for strategic development of TOT BIOPHARM pipeline drugs, from IND to NDA.
- Clinical head for Taiwan and Korea, BeiGene 2016/1-2017/4
- Director of TTY Oncology translational research center, TTY Biopharm, 2007/9 to 2015/12. ISO17025 certified
- Attending physician, National Health Research Institutes in Taipei VGH. 1991-2007
- Visiting Scientist at the IDB, NCI, NIH, US in 1994
- Board Certified Internal Medicine, Hematology, and Clinical Oncology, Taiwan.
- University of the Witwatersrand Medical School 1978-1983.

Introduction to Chinese Antibody Society and mAbTalk

Daotian Fu, PhD, President, RemeGen

Coming Soon!

Next-Generation Antibody-Drug Conjugates

Christoph Rader, PhD, Associate Dean, The Scripps Research Institute

With a focus on their biochemical building blocks, this presentation will provide an overview of next-generation antibody-drug conjugates (ADCs) that are site-specifically assembled using (i) chemical conjugation strategies based on natural and unnatural amino acids, and (ii) enzymatic conjugation strategies.

A novel ADC platform and the ADCs generated from the platform in the targeted treatment of cancer

Yongxin Zhao, PhD, President, DAC Biotech

Challenges of ADC Development;
How to address off- and on-target toxicities through optimizing Linker/Payload complex;
Hangzhou DAC’s ADC platform and development of the ADCs;
The series of ADCs generated from the platform in vitro, in vivo and the clinical activities.

Novel Linker Technologies for Generating ADCs for Cancer Therapy

Kyoji Tsuchikama, PhD, Assistant Professor, The University of Texas Health Science Center at Houston

• ADCs are an emerging drug class for the treatment of cancers
• While promising, further improvement in linker and conjugation chemistries is crucial to generate truly efficacious ADCs
• The branched linker allowed for the construction of homogeneous ADCs with multiple payloads, leading to improved therapeutic efficacy
• ADCs constructed using the novel cleavable linker showed remarkable therapeutic efficacy in xenograft mouse models of breast and other cancers

Break

Organizer, , The Chinese Antibody Society

Coming Soon!

Advancing ADCs for Transformative Cancer Therapies

Shan Jiang, PhD, Executive Director, Pharmaceutical Sciences, Seagen Inc.

Presentation outline
-IntroductionoUnwavering Focus on Transformative Oncology Therapies
-Seagen’s development directions
- ADC technologies and beyondoPipeline overview
-Recent experience from ADC development and FDA submissions
-Conclusion

Challenges in the Clinical Development of Antibody Drug Conjugates

Jacqueline Ming Liu, MD, Chief Medical Officer, TOT Biopharm

- Unmet medical need: Development pathway protracted, essential to conform to medical/ethical and scientific guidelines

- Targeting antibody drug conjugate: universal indication(s)? How important is target density? Or is a powerful bystander effect more important?

- Safety issues: the small molecules in the ADC determines adverse event spectrum, and thus MTD and phase 2 recommended dose.

- Pharmacokinetics and immunogenicity: Should all small molecules be administered at the same dose?

ADC Product Quality Development and Control

Xinfang Li, PhD, President, MabPlex

ADC therapeutics is a complex product. Both payload (linker/payload) and target binding molecule can be used as therapeutics. It is critical to control the quality for final ADC DS and DP. However, the quality control for payload and target binding molecule plays significant roles in terms ADC product quality and development cost. In this paper ADC product quality development and control experience will be shared.

2021 mAbTalk symposium

New Horizon of Antibody Drug Conjugate (ADC)

Overview

Sponsors

Platinum

Gold

Premium Sponsor

Premium

Silver

Speakers

Agenda

FAQ of Meeting Registration

Is this event free to public?

How do I register this event?

Can I connect from outside of US?

Is there any networking opportunity in this event? 如何加入参会者微信群？

I am having technical issues. Whom should I contact?